Enoch, Jamie
Ghulakhszian, Arevik
Sekhon, Mandeep
Crabb, David P.
Taylor, Deanna J.
Dinah, Christiana
Funding for this research was provided by:
City, University of London (Higher Education Innovation Fund)
Apellis Pharmaceuticals (AMR-000001)
Article History
Received: 5 January 2023
Accepted: 21 September 2023
First Online: 30 September 2023
Declarations
:
: The study received a favourable opinion from the Proportionate Review Subcommittee of the NHS South Central–Berkshire Research Ethics Committee on 10 March 2021 (REC reference: 21/SC/0085). Full ethical approval from the Health Research Authority was granted on 23 March 2021 (IRAS Project ID: 287824). Written informed consent to participate in the study was obtained from each participant. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.
: Not applicable.
: Jamie Enoch, Arevik Ghulakhszian and Mandeep Sekhon declare that they have no competing interests. David P Crabb reports grants from Roche, grants and personal fees from Santen, grants and personal fees from Apellis, grants from Allergan, personal fees from Thea, personal fees from Bayer and personal fees from Centervue, outside the submitted work. DPC receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant 116076 (Macustar). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA). The communication reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein. Deanna J Taylor holds a research grant from Apellis. Christiana Dinah has served on advisory boards for Novartis, AbbVie, Ora Clinical, Roche and Apellis. CD is on the scientific advisory board for Ora Clinical, has received speaker fees from Roche and Novartis and holds a research grant from Apellis.